Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study

Article Dermatology

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study

R. Oliver et al.

Summary: The study investigated the dosing interval during bimekizumab maintenance therapy to maintain clear skin and provide information for phase III studies.

BRITISH JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results

Nina Magnolo et al.

Summary: The study evaluated the efficacy and safety of two secukinumab dosage regimens in pediatric patients with moderate to severe plaque psoriasis, showing both doses were superior to historical placebo and well tolerated by the patients.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center

Seung-Won Jung et al.

Summary: This study compared the efficacy, safety, and drug survival of three commonly used psoriasis biologics and identified factors affecting drug survival. Guselkumab showed superior long-term response and complete remission compared to other biologics, while ustekinumab had lower efficacy. All three biologics had similar safety profiles, but had different side effects.

BIOMEDICINES (2022)

添加到收藏夹

Review Immunology

Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review

Jin Bu et al.

Summary: Psoriasis is a chronic autoimmune inflammatory disease that affects not only the skin, but also other systems of the body and mental health. Recent studies have shown associations between psoriasis and various systemic diseases, including the skin system, reproductive system, and oral and ocular systems, as well as mental health diseases, due to a shared immune-inflammatory mechanism. This review summarizes epidemiological evidence from the past 5 years, supporting the association between psoriasis and important and/or newly reported systemic diseases, aiming to improve the management of people with psoriasis.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Dermatology

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial

A. Blauvelt et al.

Summary: In the IXORA-R head-to-head trial, ixekizumab was superior to guselkumab in clearing nails and noninferior in achieving complete skin clearance at week 24. Ixekizumab cleared skin faster and provided greater cumulative benefit for patients with moderate-to-severe plaque psoriasis compared to guselkumab. Overall, the safety findings for ixekizumab were consistent with its known safety profile.

BRITISH JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Health Care Sciences & Services

Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study

Hua Zhong et al.

Summary: This study explored the impact of psoriasis on the quality of life of patients by conducting qualitative interviews with 22 patients in eastern China. The results indicated that psoriasis affects patients' symptoms, psychological well-being, and financial status, providing valuable insights for future research on the topic.

HEALTH AND QUALITY OF LIFE OUTCOMES (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Secukinumab: A Review in Psoriatic Arthritis

Hannah A. Blair

Summary: Secukinumab is an effective treatment for PsA across all key domains, with low rates of adverse effects and sustained long-term efficacy. It is a useful alternative to TNFi and other bDMARDs for adult patients with active PsA.

DRUGS (2021)

添加到收藏夹

Review Rheumatology

Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs

Gurjit S. Kaeley et al.

Summary: This review article discusses the advances in diagnostic techniques and treatment options for psoriatic nail disease, emphasizing the association between NP and PsA. The importance of accurately diagnosing and treating NP to prevent nail damage and delay the onset of joint disease is highlighted. Further research is needed to improve the management of PsD due to the lack of standardized NP scoring systems and well-defined treatment guidelines.

JOURNAL OF RHEUMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Kristian Reich et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Kenneth B Gordon et al.

LANCET (2021)

添加到收藏夹

Article Dermatology

Psoriasis Prevalence in Adults in the United States

April W. Armstrong et al.

Summary: The prevalence of psoriasis among US adults was 3.0%, with no significant differences in prevalence by gender, race/ethnicity, marital status, education, income, or medical insurance status. The prevalence has remained stable since 2003.

JAMA DERMATOLOGY (2021)

添加到收藏夹

Article Health Care Sciences & Services

Ixekizumab May Improve Renal Function in Psoriasis

Giuseppe Fabrizio Amoruso et al.

Summary: This case report discusses a patient with stage-three chronic renal failure who showed improvement after treatment with ixekizumab. Blocking IL17A may be helpful in treating autoimmune and inflammatory conditions such as psoriasis, potentially reducing the impact on renal function. Further research is needed to confirm the effectiveness of this drug in renal conditions.

HEALTHCARE (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology